Article Text
Abstract
It is reported that lncRNA KCNQ1 opposite strand/antisense transcript 1 (KCNQ1OT1) is oncogenic in many cancers. This work aimed at probing into its expression and biological functions in retinoblastoma (RB) as well as its regulatory effects on miR-153-3p and hypoxia-inducible factor-1α (HIF-1α). In our study, RB samples in pair were collected, and quantitative real-time PCR (qRT-PCR) was employed for examining the expression levels of KCNQ1OT1, miR-153-3p and HIF-1α. KCNQ1OT1 short hairpin RNAs were transfected into SO-Rb50 and HXO-RB44 cell to inhibit the expression of KCNQ1OT1. The proliferative activity, colony formation ability and apoptosis were examined through cell counting kit-8 assay, colony formation assays, Transwell assay and flow cytometry, respectively. qRT-PCR and western blot analysis were used for analyzing the changes of miR-153-3p and HIF-1α induced by KCNQ1OT1. The regulatory relationships between miR-153-3p and KCNQ1OT1, miR-153-3p and HIF-1α were examined by dual luciferase reporter gene assay and RNA-binding protein immunoprecipitation assay. The results of our study showed that KCNQ1OT1 expression was markedly enhanced in RB tissue samples, and KCNQ1OT1 knockdown had an inhibitory effect on the proliferation, migration, invasion and viability of RB cells. There were two validated binding sties between KCNQ1OT1 and miR-153-3p, and KCNQ1OT1 negatively regulated the expression of miR-153-3p in RB cells. HIF-1α was a target gene of miR-153-3p, and could be positively regulated by KCNQ1OT1. In conclusion, our study indicates that KCNQ1OT1 can increase the malignancy of RB cells via regulating miR-153-3p/HIF-1α axis.
- eye diseases
- hereditary
Statistics from Altmetric.com
Footnotes
YW and JW are joint first authors.
Contributors YW and JW conceived and designed the experiments. YW, JW and HH performed the experiments. YW, JW and XL exercised statistical analysis. YW and JW wrote the manuscript.
Funding Innovation and Entrepreneurship Scientific Research Project of Lanzhou (Approval No. 2016-RC-5).
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval The present research was endorsed by the Ethics Committee of the No. 1 People’s Hospital of Lanzhou (Approval No. 202006-1), and conducted strictly following the Declaration of Helsinki.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement The data used to support the findings of this study are available from the corresponding author on request.